Cleo Diagnostics (ASX:COV) EV-to-EBIT : (As of May. 11, 2024)

View and export this data going back to 2023. Start your Free Trial

What is Cleo Diagnostics EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Cleo Diagnostics's Enterprise Value is A$23.85 Mil. Cleo Diagnostics does not have enough years/quarters to calculate its EBIT for the trailing twelve months (TTM) ended in Dec. 2023. Therefore, GuruFocus does not calculate Cleo Diagnostics's EV-to-EBIT at this moment.

The historical rank and industry rank for Cleo Diagnostics's EV-to-EBIT or its related term are showing as below:

ASX:COV' s EV-to-EBIT Range Over the Past 10 Years
Min: -63.63 Med: 0 Max: 0
Current: -6.3

ASX:COV's EV-to-EBIT is ranked worse than
100% of 455 companies
in the Medical Devices & Instruments industry
Industry Median: 20.82 vs ASX:COV: -6.30

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Cleo Diagnostics's Enterprise Value for the quarter that ended in Dec. 2023 was A$13.02 Mil. Cleo Diagnostics does not have enough years/quarters to calculate its EBIT for the trailing twelve months (TTM) ended in Dec. 2023. Therefore, GuruFocus does not calculate Cleo Diagnostics's Earnings Yield (Joel Greenblatt) % at this moment.

Cleo Diagnostics EV-to-EBIT Historical Data

The historical data trend for Cleo Diagnostics's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cleo Diagnostics EV-to-EBIT Chart

Cleo Diagnostics Annual Data

Trend

Jun23

EV-to-EBIT

Cleo Diagnostics Semi-Annual Data
	Dec22	Jun23	Dec23
EV-to-EBIT	-	-	-

Competitive Comparison of Cleo Diagnostics's EV-to-EBIT

For the Medical Devices subindustry, Cleo Diagnostics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cleo Diagnostics's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Cleo Diagnostics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Cleo Diagnostics's EV-to-EBIT falls into.

Cleo Diagnostics EV-to-EBIT Calculation

Cleo Diagnostics's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	23.848	/
	=

Cleo Diagnostics (ASX:COV) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Cleo Diagnostics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 )	=	EBIT	/	Enterprise Value (Q: Dec. 2023 )
	=		/	13.022
	=	%

Cleo Diagnostics EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Cleo Diagnostics's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Cleo Diagnostics (ASX:COV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cleo Diagnostics Ltd (ASX:COV) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

480 Collins Street, Level 2, Melbourne, VIC, AUS, 3000

Website

https://www.cleodx.com

Cleo Diagnostics Ltd is focused on the development of non-invasive blood-based IVD tests to detect the presence, and recurrence, of ovarian cancer. The Company's first product to market is intended to be the Triage Test which has to date produced strong results to accurately differentiate patients with malignant ovarian cancer from those with benign gynaecological conditions. The Company aims to improve the diagnostic process and procedures for detecting ovarian cancer and, in this regard, improve quality-of-life outcomes for patients who have been diagnosed with ovarian cancer.

Cleo Diagnostics (ASX:COV) Headlines

No Headlines